NYSE: DVA · Medical Care Facilities

DaVita (DVA) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values DaVita (DVA) at $212.79 a share. The stock last closed at $173.00, which puts the model's fair value 23.0% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 17 Nov 2026. DaVita Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$212.79midpoint of 2,000 simulations
Last close$173.00NYSE: DVA
Gap to fair value+23.0%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $210.28 to $212.79 (+1.2%). The peer group changed: most of the move.

What the model makes of itThe price of $173.00 is 23.0% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 1 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 10 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give DVA?

The calibrated range for DVA over 63 trading days is $153.00 to $196.83. It sits around the last close, and its width comes from the volatility that DVA's own options imply (37% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $133.43 to $308.85. In 64% of the simulations the fair value came out above the price the model ran on.

$52.08$473.25
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $212.79. Dashed line: the last close, $173.00.

Faircurve Insights · 14 Nov 2026

DaVita Inc. (DVA) provides kidney dialysis treatments and comprehensive renal care to people with chronic kidney failure. It operates in healthcare, within medical care facilities.

Faircurve's model put the fair value at $212.79 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $210.28, so the fair value moved +1.2%. In the model's own words, the peer group changed: most of the move. The calibrated range over 63 trading days is $152.02 to $201.04. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations refreshed on 14 Nov 2026. The evidence grade is Medium. It reflects how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The model's overall quality score is 71 out of 100, a composite of six factors scored against comparable companies. Three stand out. Capital discipline scores 89, with net buybacks at 14.8% of market value against a peer median of 1.5%. Earnings quality scores 85, with free cash flow to net income at 1.41x against a peer median of 1.38x. The balance sheet scores 23, with net debt to EBITDA at 4.61x against a peer median of 3.14x. The model compares it with ten comparable companies.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does DVA report earnings, and how has the stock reacted?

DaVita's next earnings report is scheduled for 1 Feb 2027. Companies can move their dates.

Options prices on 17 Nov 2026 imply a move of about 8.5% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. DVA's 30 day implied volatility works out to about 10.7% over one month.

On 12 Nov 2026 DVA moved 5.1% in one session, against the 2.2% a day that options had priced: 2.3 times the implied size.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DVA's last 8 reports, ignoring direction, was 8.4%.

0%10%20%30%10.5%0.2%12 May '258.5%8.4%5 Aug '259.4%8.4%29 Oct '2513.4%23.2%2 Feb '2614.9%25.8%5 May '2611.1%19.3%4 Aug '2613.5%6.4%28 Oct '2612.7%1.9%29 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in DVA

5%10%15%20%29 Oct '26 report28 Oct '26 report4 Aug '26 report5 May '26 report2 Feb '26 report11% at 17 Nov '2621 Nov '2517 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 10% on 21 Nov 2025, reached 18% on 23 Oct 2026 and reads 11% on 17 Nov 2026. The marks are report dates.

How does DVA score on business quality?

DaVita's overall quality score is 71 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.7911.8%ROIC7.0%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).851.41xFCF / net income1.38x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.516.5%Revenue growth, trailing6.5%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.8914.8%Net buybacks / market value1.5%
Balance sheetNet debt to EBITDA and interest coverage.234.61xNet debt / EBITDA3.14x
StabilityDownside volatility of the EBITDA margin over the last five years.841.0 ptsEBITDA margin downside volatility, 5y2.5 pts

How does DVA compare with similar companies?

The companies in medical care facilities closest to DaVita in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ENSG The Ensign Group, Inc.$186.02$174.98-5.9%Fairly valued
UHS Universal Health Services, Inc.$191.98$310.03+61.5%Gap wider than 60%
EHC Encompass Health Corporation$137.88$139.30+1.0%Fairly valued
CHE Chemed Corporation$546.75$568.98+4.1%Fairly valued
CON Concentra Group Holdings Parent, Inc.$42.38$43.92+3.6%Fairly valued
THC Tenet Healthcare Corporation$282.07$371.67+31.8%Undervalued
OPCH Option Care Health, Inc.$31.63$32.92+4.1%Fairly valued
HIMS Hims & Hers Health, Inc.$17.55$21.46+22.3%Undervalued

What the comparable companies' multiples alone would give for DVA, the peer-implied price, is $382.82 a share on this run. The fair value weighs that against the company's own multiple.

All medical care facilities stocks ranked by gap to fair value

DaVita at a glance

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure.

Market value
$11.0B
Sector
Healthcare
Industry
Medical Care Facilities
Revenue expected, next twelve months
$14.6B
Consensus revenue growth, next fiscal year
+4.0%
Analysts with estimates
4
Beta to the US market
-0.24
First valued by Faircurve
1 May 2026

At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. DVA was among them.

How the fair value is worked out: the model prices DaVita on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for DVA was $210.28. As of 14 Nov 2026 it is $212.79, a change of +1.2%. The peer group changed: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about DaVita's valuation

Is DaVita stock undervalued or overvalued?

On Faircurve's model, DVA reads as Undervalued as of 14 Nov 2026. The model's fair value is $212.79 a share against a last close of $173.00, a gap of +23.0%.

What is DVA's fair value?

$212.79 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $133.43 to $308.85.

What price range does the model give DVA?

$153.00 to $196.83 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does DaVita report earnings next?

The next report is scheduled for 1 Feb 2027. Companies can move their dates.

How much has DVA moved on past earnings reports?

Across its last 8 reports the median two session move was 8.4%, ignoring direction. The largest was +25.8% around the report of 5 May 2026.

How confident is the model in this valuation?

The model's evidence grade for DVA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on DVA

The model has an idea open on DVA under Scorecard Leaders since 10 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DVA with their outcomes. A free account is enough.

Keep reading